If granted, the test’s approval process could be accelerated. The submission comes after two clinical studies conducted on the test showed consistently positive results, according to a July 9 news release from Mainz.
The test combines a traditional fecal immunochemical test with special biomarkers, alongside artificial intelligence and machine-learning algorithms.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.